Atria Wealth Solutions, Inc. Alaunos Therapeutics, Inc. Transaction History

Atria Wealth Solutions, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 02, 2024	BUY	$0.04 - $0.13 $3,620 - $11,765	90,500 Added 200.22%	135,700 $9,000
Q2 2023 Aug 03, 2023	BUY	$0.43 - $0.65 $2,150 - $3,250	5,000 Added 12.44%	45,200 $23,000
Q1 2023 Aug 22, 2023	SELL	$0.46 - $0.81 $2,300 - $4,050	-5,000 Reduced 11.06%	40,200 $25,000
Q4 2022 Aug 30, 2023	SELL	$0.5 - $261.0 $2,500 - $1.31 Million	-5,000 Reduced 11.06%	40,200 $26,000
Q2 2022 Aug 15, 2022	BUY	$0.41 - $1.24 $16,482 - $49,848	40,200 New	40,200 $50,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Atria Wealth Solutions, Inc., based on Form 13F filings with the SEC.

Stay updated on Atria Wealth Solutions, Inc. with notifications on news.